423 related articles for article (PubMed ID: 20394887)
1. Basal insulins: Pharmacological properties and patient perspectives.
Abrahamson MJ
Prim Care Diabetes; 2010 Apr; 4 Suppl 1():S19-23. PubMed ID: 20394887
[TBL] [Abstract][Full Text] [Related]
2. Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir.
Peterson GE
Curr Med Res Opin; 2006 Dec; 22(12):2613-9. PubMed ID: 17166343
[TBL] [Abstract][Full Text] [Related]
3. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes.
Klein O; Lynge J; Endahl L; Damholt B; Nosek L; Heise T
Diabetes Obes Metab; 2007 May; 9(3):290-9. PubMed ID: 17391154
[TBL] [Abstract][Full Text] [Related]
4. The role of new basal insulin analogues in the initiation and optimisation of insulin therapy in type 2 diabetes.
Baxter MA
Acta Diabetol; 2008 Dec; 45(4):253-68. PubMed ID: 18766296
[TBL] [Abstract][Full Text] [Related]
5. Insulin analogs versus human insulin in type 2 diabetes.
Migdalis IN
Diabetes Res Clin Pract; 2011 Aug; 93 Suppl 1():S102-4. PubMed ID: 21864739
[TBL] [Abstract][Full Text] [Related]
6. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial.
Fajardo Montañana C; Hernández Herrero C; Rivas Fernández M
Diabet Med; 2008 Aug; 25(8):916-23. PubMed ID: 18959604
[TBL] [Abstract][Full Text] [Related]
7. A review of basal insulins.
Barnett AH
Diabet Med; 2003 Nov; 20(11):873-85. PubMed ID: 14632712
[TBL] [Abstract][Full Text] [Related]
8. Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia.
Johansen OE; Vanberg PJ; Kilhovd BK; Jørgensen AP
Vasc Health Risk Manag; 2009; 5(1):121-8. PubMed ID: 19436668
[TBL] [Abstract][Full Text] [Related]
9. Insulin detemir: A historical perspective on a modern basal insulin analogue.
Meneghini L; Liebl A; Abrahamson MJ
Prim Care Diabetes; 2010 Apr; 4 Suppl 1():S31-42. PubMed ID: 20394890
[TBL] [Abstract][Full Text] [Related]
10. [Long-acting insulin analogs: progressing slowly].
Holleman F; Hoekstra JB
Ned Tijdschr Geneeskd; 2004 Aug; 148(34):1668-9. PubMed ID: 15453117
[TBL] [Abstract][Full Text] [Related]
11. Refining basal insulin therapy: what have we learned in the age of analogues?
Devries JH; Nattrass M; Pieber TR
Diabetes Metab Res Rev; 2007 Sep; 23(6):441-54. PubMed ID: 17668418
[TBL] [Abstract][Full Text] [Related]
12. Insulin detemir: a new basal insulin analogue.
Soran H; Younis N
Diabetes Obes Metab; 2006 Jan; 8(1):26-30. PubMed ID: 16367879
[TBL] [Abstract][Full Text] [Related]
13. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart.
Vague P; Selam JL; Skeie S; De Leeuw I; Elte JW; Haahr H; Kristensen A; Draeger E
Diabetes Care; 2003 Mar; 26(3):590-6. PubMed ID: 12610006
[TBL] [Abstract][Full Text] [Related]
14. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes.
Haak T; Tiengo A; Draeger E; Suntum M; Waldhäusl W
Diabetes Obes Metab; 2005 Jan; 7(1):56-64. PubMed ID: 15642076
[TBL] [Abstract][Full Text] [Related]
15. Does insulin detemir have a role in reducing risk of insulin-associated weight gain?
Hermansen K; Davies M
Diabetes Obes Metab; 2007 May; 9(3):209-17. PubMed ID: 17391147
[TBL] [Abstract][Full Text] [Related]
16. Observational, open-label study of type 1 and type 2 diabetes patients switching from human insulin to insulin analogue basal-bolus regimens: insights from the PREDICTIVE study.
Hermansen K; Dornhorst A; Sreenan S
Curr Med Res Opin; 2009 Nov; 25(11):2601-8. PubMed ID: 19739940
[TBL] [Abstract][Full Text] [Related]
17. Insulin degludec. Uncertainty over cardiovascular harms.
Prescrire Int; 2014 Jun; 23(150):149. PubMed ID: 25121146
[TBL] [Abstract][Full Text] [Related]
18. Insulin detemir: new drug. A second long-acting insulin analogue: many uncertainties, few advantages.
Prescrire Int; 2006 Oct; 15(85):163-7. PubMed ID: 17121210
[TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness and safety of different basal insulins in a real-world setting.
Ji L; Zhang P; Zhu D; Lu J; Guo X; Wu Y; Li X; Ji J; Jia W; Yang W; Zou D; Zhou Z; Gao Y; Garg SK; Pan C; Weng J; Paul SK;
Diabetes Obes Metab; 2017 Aug; 19(8):1116-1126. PubMed ID: 28230322
[TBL] [Abstract][Full Text] [Related]
20. Meta-analysis of individual patient data to assess the risk of hypoglycaemia in people with type 2 diabetes using NPH insulin or insulin glargine.
Home PD; Fritsche A; Schinzel S; Massi-Benedetti M
Diabetes Obes Metab; 2010 Sep; 12(9):772-9. PubMed ID: 20649629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
